Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
RV1162 is a new medicine being developed for possible treatment of smoking related lung
disease (also known as chronic obstructive pulmonary disease - COPD). The main purpose of
this study is to investigate the safety, tolerability and pharmacokinetics of single and
repeat doses of RV1162.